Clinical Trial Update: Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating Tremelimumab and/or MEDI4736 (durvalumab) in combination with radiation therapy for unresectable pancreatic cancer has com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer
• Pancreatic Neoplasms

Drugs mentioned

• MEDI4736 (Durvalumab)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Pancreatic Neoplasms, Pancreatic Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-07-17